Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, phloretin partly inhibited renal glucose transporter 9 (GLUT9) and promoted urinary UA excretion in HUA mice.
|
31790902 |
2020 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
In hyperuricemic rats, high EU (400 mg/kg) significantly reduced SUA levels to 253.85 μmol/L, and increased OAT1 and OAT3 levels, but decreased URAT1 and GLUT9, compared to the hyperuricaemia group (p < 0.05).
|
30843748 |
2019 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Type 2 renal hyperuricemia (RHUC2) is caused by a mutation in the SLC2A9 gene, which encodes a high‑capacity glucose and urate transporter, glucose transporter (GLUT)9.
|
31638209 |
2019 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For rare variants, six single nucleotide variations (SNVs) p.T21I and p.G13D in SLC2A9, p.W50fs, p.Q382L, p.V547L and p.E458K in SLC22A12, occurred in totally six hypouricemia subjects and were absent in HUA and normal controls.
|
31131560 |
2019 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
CLA ameliorates hyperuricemia along with insulin resistance and renal inflammatory, which may be associated with the suppression of renal GLUT9 and URAT1 in fructose-fed rats.
|
30913372 |
2019 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In turn, some of these single nucleotide polymorphisms in SLC2A9 may increase the risk of hyperuricemia.
|
31016517 |
2019 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Research on the pharmacodynamics and mechanism of Fraxini Cortex on hyperuricemia based on the regulation of URAT1 and GLUT9.
|
29990831 |
2018 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The SLC2A9 mutation increases the risk for T2DM complicated HUA in Chinese population, which suggested that intron variants between two relatively conserved exons could also be associated with diseases.
|
30087870 |
2018 |
Hyperuricemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Effects of Chicory on Serum Uric Acid, Renal Function, and GLUT9 Expression in Hyperuricaemic Rats with Renal Injury and <i>In Vitro</i> Verification with Cells.
|
30622589 |
2018 |
Hyperuricemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we found the significant decrease in protein expression of URAT1 and GLUT9, and the significant increase in protein expression of OAT1 in the kidney in AFPR treated groups compared to the model groups of hyperuricemia.
|
29490297 |
2018 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Systematic analysis of Glut9 mutants confirms Glut9 as putative target for the treatment of hyperuricemia and brings new insights in Glut9 structure - function.
|
29967582 |
2018 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Phloretin attenuates hyperuricemia-induced endothelial dysfunction through co-inhibiting inflammation and GLUT9-mediated uric acid uptake.
|
28402018 |
2017 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
G. pensylvanicum extract showed activity in reducing serum uric acid (Sur) through effect renal glucose transporter 9 (GLUT9), organic anion transporter 1 (OAT1) and urate transporter 1 (URAT1) mainly and inhibited XO activity in vivo of mice with PO induced hyperuricemia.
|
28623927 |
2017 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, compared to the hyperuricemia control, OAT1 was elevated remarkably in mice drugged with GAE and GAW, while GLUT9 was significantly decreased.
|
29379442 |
2017 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Two important pathways determining hyperuricemia have been confirmed (renal and gut excretion of uric acid with glycolysis now firmly implicated).Major urate loci are SLC2A9 and ABCG2.
|
25889045 |
2015 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we set to investigate whether the exon 9 of SLC2A9 gene variations is associated with HUA complicated with Type 2 DM (T2DM) in the Chinese male Han population.
|
25476142 |
2015 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Complex analysis of urate transporters SLC2A9, SLC22A12 and functional characterization of non-synonymous allelic variants of GLUT9 in the Czech population: no evidence of effect on hyperuricemia and gout.
|
25268603 |
2014 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load.
|
23349133 |
2013 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The multidrug ATP-binding cassette, subfamily G, 2 (ABCG2) transporter was recently identified as an important human urate transporter, and a common mutation, a Gln to Lys substitution at position 141 (Q141K), was shown to cause hyperuricemia and gout.
|
23493553 |
2013 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results highlight a possible role of sex hormones in the regulation of ABCG2 urate transporter and its potential implications for the prevention, diagnosis, and treatment of hyperuricemia and gout.
|
23552988 |
2013 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Genome-wide association scans for genes regulating serum urate concentrations have identified two major regulators of hyperuricaemia- the renal urate transporters SLC2A9 and ABCG2.
|
20472486 |
2011 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The polymorphism rs6855911 in SLC2A9 may be a genetic marker to assess risk of hyperuricemia among Chinese male Han population.
|
20972595 |
2011 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
The Dalmatian dog model of hyperuricosuria and hyperuricemia underscores the importance of SLC2A9 for uric acid transport in mammals.
|
18989453 |
2008 |